Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk Ventilation 20% Recovery time 26% Hospitalization time 24% Kumari et al. Vitamin C for COVID-19 RCT LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? RCT 150 patients in Pakistan Faster recovery (p=0.0001) and shorter hospitalization (p=0.0001) Kumari et al., Cureus 12(11): e11779, doi:10.7759/cureus.11779 Favors vitamin C Favors control
The Role of Vitamin C as Adjuvant Therapy in COVID-19
Kumari et al., Cureus 12(11): e11779, doi:10.7759/cureus.11779
Kumari et al., The Role of Vitamin C as Adjuvant Therapy in COVID-19, Cureus 12(11): e11779, doi:10.7759/cureus.11779
Nov 2020   Source   PDF  
  All Studies   Meta
RCT 150 hospitalized patients in Pakistan showing 26% faster recovery, p < 0.0001. 36% lower mortality, not statistically significant due to the small number of events. Dosage was 50 mg/kg/day of intravenous vitamin C.
risk of death, 36.4% lower, RR 0.64, p = 0.45, treatment 7 of 75 (9.3%), control 11 of 75 (14.7%), NNT 19.
risk of mechanical ventilation, 20.0% lower, RR 0.80, p = 0.67, treatment 12 of 75 (16.0%), control 15 of 75 (20.0%), NNT 25.
recovery time, 26.0% lower, relative time 0.74, p < 0.001, treatment 75, control 75, days to symptom-free.
hospitalization time, 24.3% lower, relative time 0.76, p < 0.001, treatment 75, control 75, days spent in hospital.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kumari et al., 30 Nov 2020, Randomized Controlled Trial, Pakistan, peer-reviewed, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Open Access Original Article DOI: 10.7759/cureus.11779 The Role of Vitamin C as Adjuvant Therapy in COVID-19 Poona Kumari 1 , Suman Dembra 2 , Pariya Dembra 3 , Fnu Bhawna 4, 5 , Ambresha Gul 6 , Basma Ali 4 , Hamza Sohail 4 , Besham Kumar 7 , Muhammad Khizar Memon 8 , Amber Rizwan 9 1. Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK 2. Medicine, Peoples University of Medical and Health Sciences for Women, Nawabshah, PAK 3. Medicine, Jinnah Sindh Medical University, Karachi, PAK 4. Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK 5. Internal Medicine, Qatar Hospital, Karachi, PAK 6. Internal Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK 7. Internal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK 8. Internal Medicine, Liaquat University of Medical and Health Sciences, Hyderabad, PAK 9. Family Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK Corresponding author: Amber Rizwan, Abstract Background and objective The anti-inflammatory properties of vitamin C (VC) and the promising results it has shown in the treatment for common cold have prompted clinicians to use it as adjuvant therapy in the treatment of COVID-19. The purpose of this study was to find out the role of VC as adjunctive therapy in coronavirus disease 2019 (COVID-19). Methodology This study was conducted from March to July 2020 in the COVID-19 unit of a tertiary care hospital in Karachi. In this randomized controlled trial (RCT), one group received the intervention [50 mg/kg/day of intravenous (IV) VC] along with the standard therapy, and the other group received standard therapy only. Data such as age, gender, vitals, and biochemical values as well as outcomes including the number of days required for treatment, hospital stay, need for ventilation, and mortality were compared between the two groups and recorded using a self-structured questionnaire. Results COVID-19 patients who received IV VC became symptom-free earlier (7.1 ± 1.8 vs. 9.6 ± 2.1 days, p-value: <0.0001) and spent fewer days in the hospital (8.1 ± 1.8 vs. 10.7 ± 2.2 days, p-value: <0.0001) compared to those who received standard therapy only. However, there was no significant difference in the need for mechanical ventilation (p-value: 0.406) and mortality (p-value: 0.31) between the two groups. Conclusion VC can significantly improve clinical symptoms in patients affected with COVID-19; however, it had no impact on mortality and the need for mechanical ventilation. More large-scale studies are required to further assess the role of VC in the treatment of COVID-19. Review began 10/30/2020 Review ended 11/20/2020 Published 11/30/2020 © Copyright 2020 Kumari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted Categories: Internal Medicine, Infectious Disease Keywords: intravenous vitamin c, covid-19, pakistan use, distribution, and reproduction in any medium, provided the original author and source are credited.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop